Health
Patient-Reported Outcomes from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Repository Corticotropin Injection (Acthar ® Gel) for Persistently Active Systemic Lupus Erythematosus – DocWire News
Introduction: We assessed patient-reported outcomes from a multicenter, randomized, double-blind, placebo-controlled study of repository corticotropin
Introduction: We assessed patient-reported outcomes from a multicenter, randomized, double-blind, placebo-controlled study of repository corticotropin injection (RCI; Acthar® Gel) in patients with persistently active systemic lupus erythematosus (SLE) despite treatment with moderate-dose glucocorticoids.
Methods: The trial enrolled adults with active SLE and moderate-to-severe rash and/or arthritis despite use of stable glucocorticoids (7.5 mg/day to 30 mg/day prednisone equivalent), antimalarials,…
-
Business14 hours ago$10,000 invested in ANZ shares 5 years ago is now worth…
-
General17 hours agoWe’ve all talked about potential economic consequences for Australia of Trump’s policies. Now they’re happening
-
General14 hours agoStephanie Scott’s murder caused a ‘seismic’ shock in Leeton, and the hurt remains
-
Noosa News24 hours agoBrisbane doctor jailed for trafficking ‘breathtaking amount’ of drugs